Profile data is unavailable for this security.
About the company
Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
- Revenue in GBP (TTM)169.67m
- Net income in GBP-154.51m
- Incorporated2005
- Employees1.24k
- LocationOxford Nanopore Technologies PLCOxford Science ParkGosling Building, Edmund Halley RoadOXFORD OX4 4DQUnited KingdomGBR
- Websitehttps://www.nanoporetech.com/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| medmix AG | 426.34m | 262.85k |
| Synsam AB (publ) | 433.35m | 22.82m |
| Revenio Group Oyj | 82.74m | 16.27m |
| Paul Hartmann AG | 2.01bn | 24.32m |
| Draegerwerk AG & Co KGaA | 2.87bn | 85.99m |
| El En SpA | 592.48m | 41.28m |
| GVS SpA | 363.50m | 11.68m |
| Xvivo Perfusion AB | 47.18m | 7.37m |
| Arjo AB (publ) | 814.66m | 38.01m |
| Oxford Nanopore Technologies PLC | 169.67m | -154.51m |
| Medartis Holding AG | 185.75m | 542.34k |
| Biotage AB | 145.38m | 17.32m |
Institutional shareholders
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 11 May 2023 | 41.71m | 4.85% |
| Storebrand Asset Management ASas of 01 Apr 2024 | 35.29m | 4.11% |
| Invesco Advisers, Inc.as of 28 Feb 2023 | 28.66m | 3.33% |
| Lansdowne Partners (UK) LLPas of 28 Feb 2023 | 28.00m | 3.26% |
| GIC Pte Ltd. (Investment Management)as of 27 Mar 2024 | 25.70m | 2.99% |
| Redmile Group LLCas of 28 Feb 2023 | 24.70m | 2.87% |
| The Vanguard Group, Inc.as of 01 Apr 2024 | 13.01m | 1.51% |
| Aberforth Partners LLPas of 01 Apr 2024 | 11.13m | 1.30% |
| Norges Bank Investment Managementas of 01 Apr 2024 | 9.42m | 1.10% |
| Aegon Asset Management UK PLCas of 01 Apr 2024 | 7.14m | 0.83% |
